谷歌浏览器插件
订阅小程序
在清言上使用

Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients.

European cardiology(2023)

引用 0|浏览1
暂无评分
摘要
Antiplatelet agents are routinely used to treat patients with chronic atherosclerotic coronary artery disease. Treatment with the addition of a low dose of rivaroxaban as dual-pathway inhibition (DPI) decreases ischaemic events at the expense of increased bleeding. At present, the balance between thrombotic and bleeding risks must be carefully weighed up when considering DPI. However, with the introduction of activated coagulation factor XI inhibitors, which have fewer bleeding effects, the use of DPI in patients with atherosclerotic cardiovascular diseases could be extended.
更多
查看译文
关键词
Anticoagulation,atherosclerosis,thrombosis,antiplatelet
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要